Press Releases
Stay updated on the latest Vistagen News and get the details about important events, public financial reports, and our product pipeline updates.
Mar 05, 2018
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/05/18 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief Executive
Feb 27, 2018
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/27/18 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief Executive
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/12/18 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported financial results for its
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/29/18 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today issued a letter to stockholders as
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/22/18 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief
Jan 03, 2018
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/03/18 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S.
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/18/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that it will present at the
Dec 13, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/13/17 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today
Dec 11, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/11/17 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders, today announced
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/08/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S.
